Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas REDWOOD CITY, Calif., Nov. 02, 2020 ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Pulmonx Inc's valve to treat a severe form of obstructive lung disease, most often characterized by shortness of breath. Treatment ...

Pulmonx ® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr ® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the ...

Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate ...

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in ...

REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the ...